According to a report released on Tuesday, India’s bioeconomy is approaching the $200 billion mark, which is a major turning point in its development, with a strong policy drive and an expanding innovation pipeline indicating the next stage of expansion.

According to a study by Endiya Partners, the bioeconomy of the nation has increased dramatically from about $10 billion in 2014 to more than $195 billion in 2026, currently accounting for about 5% of the GDP.

India, which has long been known as the “Pharmacy of the World” for producing about 20% of the world’s generics and more than 60% of vaccines, is currently shifting toward an innovation-driven biopharma ecosystem that emphasizes cutting-edge therapies and advanced technology platforms.

The report emphasized that India is at a turning point because of favorable regulations, policy actions, and growing international recognition of its clinical-stage assets.

It also emphasized important government programs that are anticipated to foster the growth of a strong innovation ecosystem, such as the Rs 10,000 crore Biopharma Shakti scheme and the Rs 1,00,000 crore Research, Development and Innovation (RDI) Fund.

Additionally, it said that recent regulatory changes, such as the implementation of a 45-day approval timeline and prior notification pathways, are expected to shorten drug development cycles by as much as four months while also alleviating bureaucratic bottlenecks.

Meanwhile, India’s cost-effective and high-velocity research ecosystem is being presented with opportunities due to structural changes in the world biopharma business, such as growing R&D expenditures, which are currently projected at $2. 2 billion per asset, and an approaching patent cliff of $300 billion.

Additionally, the report highlighted the ‘Recruitment Alpha’ advantage that Indian biotech businesses have, which allows them to enroll patients far more quickly and advance drug candidates to Phase II trials at significantly lower costs than their international competitors.

It further stated that Indian businesses are able to make many parallel bets in drug development thanks to this advantage, which increases their chances of overall success.

The report did, however, warn of persistent challenges, such as inadequate pilot-scale GMP infrastructure, a lack of late-stage finance, talent shortages, and the necessity for better translational research skills.

India’s biopharma ecosystem, which includes more than 600 research institutes, 2,500 businesses, and 100 incubators, is well-prepared to facilitate the next stage of development despite these limitations.

According to the study, India might become a global center for affordable, high-quality biopharma innovation if there is ongoing government support and stronger ecosystem collaboration.